A rise in cardiac output and a fall in arterial oxygen tension are well known side effects of bronchodilator drugs, particularly 3-adrenergic agonists. In recent years, fenoterol (Berotec), an effective (3-adrenergic agonist, has been used at increasing rates in asthmatic subjects, as well as in patients with chronic obstructive pulmonary disease 
MATERIALS AND METHODS
Fourteen patients with COPD, defined by standard criteria, 24 who were free of cardiac disease by clinical and routine laboratory data, were studied. They were all in stable condition with therapy, which included 3-adrenergic agonist drugs. Two days before the study, all bronchodilator drugs were discontinued. One day before the study the ventilatory response one hour following 400u,g of inhaled fenoterol was tested; seven patients in whom the forced expiratory volume in one second (FEVJ increased by <15 percent were considered to have fixed airflow obstruction (group 1; all male patients); and in the other seven patients, FEV, was increased by >20 percent, and the patients were considered to have a significant reversible component of airflow obstruction (group 2; six male patients and one female patient). The pertinent baseline characteristics of the two groups are given in Table 1 .
Maximal work capacity was assessed on the day preceding the study by exercising the patients, in the supine position, on a bicycle ergometer (Bosch ERG and ELP 500) with workloads increased by 25 W every two minutes until 90 percent of the maximal predicted heart rate was reached. 25 Exercise was terminated sooner if exhaustion ensued or if systolic blood pressure rose to 200 mm Hg or more.
The experimental design on the day of study is shown in Figure  1 . Baseline measurements after one-half hour of rest in the supine position included the folowing: heart rate and cardiac output byimpedance cardiography (Minnesota Impedance Cardiograph 304B and Microcomputer Surcom Inc.); oxygen consumption (Voj) by an
open-circuit face mask (Oxylog; P.K. Morgan Ltd); arterial blood gas levels (Radiometer analyzer BMS 2 Mk2); arterial blood hemoglobin and oxygen saturation (MBA Co-oxymeter). Using the tracings obtained with the impedance technique (Fig 2 and 3) , values for the following variables were determined for each heart beat: instantaneous heart rate, from the R-R interval preceding each heart beat; dZ/dt (in ohms per second) from the impedance wave (maximal signal height from the baseline); and left ventricular ejection time (t in seconds) from the first and second heart-sound interval. Stroke volume (SV) was calculated by computer using the standard impedance formula of Kubicek et al: 28 SV = pt (dZ/dt) (L 2 / Zo 2 ), where blood resistivity (p) was calculated for each subject based on venous hematocrit, 27 and L was the anterior midsternal distance between the inner electrodes; 28 t, dZ/dt, and Zo were as defined previously.
Immediately after collection of baseline data, patients performed submaximal exercise with a fixed workload (25 W less than maximal) for five minutes (zero to five minutes). During the last minute of exercise, all of the previous measurements were repeated. Thirty minutes were then allowed for complete recovery (5 to 35 minutes). At 35 minutes, fenoterol (400(AG by inhalation) was given. Approximately one hour later (90 to 95 minutes), baseline and exercise measurements were repeated using a protocol identical to the one described previously
The following calculations were applied: 29 rial oxygen flow (AF; in milliliters per minute) = CO X Ca02; and (5) oxygen extraction (OE; in percent) = (Vo2 (in liters per minute) x 100)/AF (in liters per minute).
Workload with the first exercise was 39 + a W (± SE) for group 1 and 54 ± 9 W for group 2; in each case the workload was the same after administration of the drug. Increases in heart rate with exercise were comparable in the two groups (group 1, + 30 beats per minute before fenoterol and +32 beats per minute after; group 2, +36 beats per minute before and + 36 beats per minute after).
Baseline data were compared between groups with Student's f-test. The effects of exercise before and after administration of fenoterol were analyzed by two-way repeated-measures analysis of variance.
Informed written consent was obtained from all patients before inclusion in the study.
RESULTS
At baseline, in contrast to group 2, where all measured and calculated parameters of oxygen transport were within the range for age-matched normal subjects in our laboratory, the patients in group 1 (with FEV, and Pa02 comparable to group 2) showed evidence of impaired oxygen transport. Cardiac output and arterial oxygen flow were decreased; hence, in order to maintain a normal Vo2, the AC(a-v)02 had to be widened, and the fraction of arterial oxygen flow extracted by the tissues had to be larger (Table 1 ). In both groups (Tables 2 and 3 The origin of the impedance signal has not been entirely established, but there is agreement that the major portion of Z comes from blood ejected into the ascending aorta. 45 This view is supported by the good linearity observed between LVSV determined impedance cardiography and LVSV determined simultaneously with the use of an electromagnetic probe in the ascending aorta. 46 -47 At our institutions, impedance cardiography has been used extensively for measuring cardiac output in human and animal studies. 48~ss The reproducibility of the technique has been confirmed. 56 Like others, we have documented good correlations between impedance cardiography and thermodilution measurements in two separate studies, one on 20 cardiac patients with a cardiac index greater than 2.0 but less than 4.5 L/min/m 2 (r = 0.784) 57 and the other on ten dialysis patients with a cardiac index greater than 2.5 but less than 5.0 L/min/m 2 (r = 0.88). 58 Most Under the conditions of the present investigation, fenoterol showed no effect in either group, at rest or after exercise, on the oxygen transport parameters investigated, indicating that the drug-induced pathophysiologic disturbances discussed previously were not operative or were not detectable with the design of our study. Hence, when indicated, the use of this drug in patients with COPD is not a potentially harmful practice. 
